245 related articles for article (PubMed ID: 33868173)
1. Everolimus Related Fulminant Hepatitis in Pancreatic Neuroendocrine Tumor With Liver Metastases: A Case Report and Literature Review.
Chang SC; Tsai CY; Liu KH; Wang SY; Hsu JT; Yeh TS; Yeh CN
Front Endocrinol (Lausanne); 2021; 12():639967. PubMed ID: 33868173
[TBL] [Abstract][Full Text] [Related]
2. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.
Yao JC; Lombard-Bohas C; Baudin E; Kvols LK; Rougier P; Ruszniewski P; Hoosen S; St Peter J; Haas T; Lebwohl D; Van Cutsem E; Kulke MH; Hobday TJ; O'Dorisio TM; Shah MH; Cadiot G; Luppi G; Posey JA; Wiedenmann B
J Clin Oncol; 2010 Jan; 28(1):69-76. PubMed ID: 19933912
[TBL] [Abstract][Full Text] [Related]
3. Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study.
Bajetta E; Catena L; Fazio N; Pusceddu S; Biondani P; Blanco G; Ricci S; Aieta M; Pucci F; Valente M; Bianco N; Mauri CM; Spada F
Cancer; 2014 Aug; 120(16):2457-63. PubMed ID: 24752410
[TBL] [Abstract][Full Text] [Related]
4. [Two Cases of Pancreatic Neuroendocrine Tumor with Liver Metastases Successfully Treated with Multidisciplinary Therapy including Multiple Surgical Resections].
Akiyama T; Yoshitomi H; Shida T; Shimizu H; Ohtsuka M; Kato A; Furukawa K; Takayashiki T; Kuboki S; Takano S; Okamura D; Suzuki D; Sakai N; Kagawa S; Miyazaki M
Gan To Kagaku Ryoho; 2015 Nov; 42(12):2397-9. PubMed ID: 26805376
[TBL] [Abstract][Full Text] [Related]
5. Multimodal therapy with aggressive hepatectomy, everolimus, and octreotide for metastatic pancreatic neuroendocrine neoplasm enables 10-year survival.
Yumoto S; Nakagawa S; Hayashi H; Ogawa D; Shiraishi Y; Sato H; Matsumoto T; Imai K; Yamashita YI; Baba H
Clin J Gastroenterol; 2022 Dec; 15(6):1136-1144. PubMed ID: 36038805
[TBL] [Abstract][Full Text] [Related]
6. A case of advanced pancreatic neuroendocrine tumor in which octreotide long-acting repeatable was effective after failure of everolimus and sunitinib.
Kitade H; Ohtsubo K; Hokkoku K; Mori M; Osamura RY; Sakuma H; Nakai M; Yano S
Int Cancer Conf J; 2019 Jan; 8(1):24-28. PubMed ID: 31149542
[TBL] [Abstract][Full Text] [Related]
7. Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-2 study.
Castellano D; Bajetta E; Panneerselvam A; Saletan S; Kocha W; O'Dorisio T; Anthony LB; Hobday T;
Oncologist; 2013; 18(1):46-53. PubMed ID: 23263288
[TBL] [Abstract][Full Text] [Related]
8. Everolimus plus octreotide long-acting repeatable in advanced neuroendocrine tumors in the routine tertiary cancer care setting: An Indian experience.
Tippeswamy R; Patil S; Sateesh CT; Shashidhara HP; Prabhudesai S; Prashanth P; Haridas KM
Indian J Cancer; 2015; 52(3):359-62. PubMed ID: 26905137
[TBL] [Abstract][Full Text] [Related]
9. Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study.
Fazio N; Granberg D; Grossman A; Saletan S; Klimovsky J; Panneerselvam A; Wolin EM
Chest; 2013 Apr; 143(4):955-962. PubMed ID: 23187897
[TBL] [Abstract][Full Text] [Related]
10. [Treatment Strategy for Non-Functional Pancreatic Neuroendocrine Tumors (P-NETs) at Kurume University Hospital].
Kawashima Y; Ishikawa H; Hisaka T; Okuda K; Akagi Y
Gan To Kagaku Ryoho; 2016 Jan; 43(1):107-10. PubMed ID: 26809536
[TBL] [Abstract][Full Text] [Related]
11. [A Case of Pancreatic Neuroendocrine Tumor(p-NET)with Long-Term Survival with Multidisciplinary Treatment].
Katsura Y; Takeda Y; Ohmura Y; Sakamoto T; Shinke G; Katsuyama S; Kawai K; Kitahara T; Hiraki M; Murakami K; Kagawa Y; Masuzawa T; Takeno A; Hata T; Murata K
Gan To Kagaku Ryoho; 2021 Mar; 48(3):394-396. PubMed ID: 33790166
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors.
Dasari A; Phan A; Gupta S; Rashid A; Yeung SC; Hess K; Chen H; Tarco E; Chen H; Wei C; Anh-Do K; Halperin D; Meric-Bernstam F; Yao J
Endocr Relat Cancer; 2015 Jun; 22(3):431-41. PubMed ID: 25900182
[TBL] [Abstract][Full Text] [Related]
13. [Two cases of neuroendocrine tumors of the pancreas with multiple liver metastases treated by use of degradable starch microspheres and octreotide].
Goto W; Shimizu S; Kotsuka M; Sakae M; Kanazawa A; Tsukamoto T; Yamashita Y; Nishiguchi Y
Gan To Kagaku Ryoho; 2014 Nov; 41(12):2139-41. PubMed ID: 25731449
[TBL] [Abstract][Full Text] [Related]
14. Metastatic neuroendocrine pancreatic tumor - Case report.
Radu EC; Saizu AI; Grigorescu RR; Croitoru AE; Gheorghe C
J Med Life; 2018; 11(1):57-61. PubMed ID: 29696066
[No Abstract] [Full Text] [Related]
15. The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan.
Liu CT; Chen MH; Chen JS; Chen LT; Shan YS; Lu CH; Su YL; Ku FC; Chou WC; Chen YY
Asia Pac J Clin Oncol; 2016 Dec; 12(4):396-402. PubMed ID: 27357443
[TBL] [Abstract][Full Text] [Related]
16. [Subcutaneous continuous injection of octreotide decreased the tumor marker levels and induced cystic necrosis of the tumors in a case of pancreatic neuroendocrine tumor with multiple hepatic metastases].
Miura M; Shibahara H; Morita K; Matsui K; Itoh Y; Shimizu J; Takeuchi A; Narita M; Nishimura D; Katada N
Nihon Shokakibyo Gakkai Zasshi; 2015 Mar; 112(3):537-46. PubMed ID: 25759229
[TBL] [Abstract][Full Text] [Related]
17. Is surgery indicated for patients with symptomatic nonfunctioning pancreatic neuroendocrine tumor and unresectable hepatic metastases?
Hung JS; Chang MC; Lee PH; Tien YW
World J Surg; 2007 Dec; 31(12):2392-7. PubMed ID: 17960455
[TBL] [Abstract][Full Text] [Related]
18. Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase III RADIANT-2 Trial.
Anthony LB; Pavel ME; Hainsworth JD; Kvols LK; Segal S; Hörsch D; Van Cutsem E; Öberg K; Yao JC
Neuroendocrinology; 2015; 102(1-2):18-25. PubMed ID: 25824001
[TBL] [Abstract][Full Text] [Related]
19. Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors.
Pusceddu S; de Braud F; Concas L; Bregant C; Leuzzi L; Formisano B; Buzzoni R
Tumori; 2014; 100(6):e286-9. PubMed ID: 25688512
[TBL] [Abstract][Full Text] [Related]
20. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.
Ricci S; Antonuzzo A; Galli L; Ferdeghini M; Bodei L; Orlandini C; Conte PF
Ann Oncol; 2000 Sep; 11(9):1127-30. PubMed ID: 11061606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
